The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. (MDCX) entered into a non-binding letter of intent through its wholly owned subsidiary, Skinject, Inc., with an undisclosed SPAC for a proposed business combination that contemplates a $135 million pre-money enterprise valuation for SkinJect. The SPAC would acquire 100% of SkinJect in exchange for newly issued common shares of the combined company, with concurrent equity financing intended to support the SKNJCT-005 study in Gorlin syndrome and preparation and submission of a potential NDA. Medicus intends to retain majority economic and voting ownership of the combined company.
Except for limited procedural provisions, the proposed terms are non-binding. Completion is subject to due diligence, definitive agreements, financing, a minimum-cash condition, required approvals, SEC filings and other closing conditions. Medicus anticipates completion in the first half of 2027. The FDA issued a “Study May Proceed” letter authorizing initiation of the planned NDA-enabling registrational Phase 2b study. A separate business-update call is scheduled for November 9, 2026, at 11:30 a.m. Eastern Time.
Medicus Pharma Ltd. (MDCX) is asking shareholders to authorize unlimited Class A preferred shares and a discretionary Common Share split of up to one pre-split share for every 50 post-split shares at its special meeting scheduled for December 2, 2026.
If approved, the board could set the terms of each preferred-share series without another shareholder vote; it says it has no present intent to issue these shares. At the maximum split ratio, the proposal would substantially reverse the 50-to-one consolidation effected October 12, 2026. The board says it does not intend to choose a ratio it expects would push the bid price below the $1.00 minimum for continued listing on The Nasdaq Capital Market.
The preferred-share and split proposals each require at least two thirds of votes cast; the adjournment proposal requires a majority. Medicus reported 1,899,338 Common Shares outstanding as of October 28, 2026.
Medicus Pharma Ltd.'s prospectus supplement identifies 64,911 common shares issuable upon exercise of warrants and updates the existing prospectus with information from the company's October 23, 2026 current report. The warrants have a $4.64 exercise price and expire November 15, 2029. On October 22, 2026, the last reported prices were $2.62 for common shares and $0.21 for Public Warrants.
Nasdaq notified Medicus on October 23, 2026 that it had regained compliance with the $1.00 minimum bid price requirement: closing bids were at least $1.00 for ten consecutive business days, from October 12 through October 23, and Nasdaq closed the matter. The notice superseded an October 20 delisting determination. Medicus stated that there can be no assurance it will maintain compliance with this or Nasdaq's other continued listing requirements.
Medicus Pharma Ltd. (MDCX) regained compliance with Nasdaq’s $1.00 minimum bid price requirement after its common shares closed at or above $1.00 for 10 consecutive business days, from October 12, 2026, through October 23, 2026.
Nasdaq’s October 20 delisting determination was superseded and rendered moot by its October 23 Compliance Notice, which closed the matter. The earlier determination followed the company’s failure to meet the October 19 deadline; Nasdaq said the company was not eligible for a second 180-calendar-day compliance period because it did not meet the $5 million stockholders’ equity requirement. Medicus said there can be no assurance it will maintain compliance with Nasdaq’s continued listing requirements.
Medicus Pharma Ltd. supplements its prospectus covering 64,911 common shares issuable upon exercise of warrants and reports a 1-for-50 share consolidation, effective October 12, 2026. The common shares began trading on a post-consolidation basis on The Nasdaq Capital Market that day. Shareholders approved a consolidation of up to 1-for-50 at the June 3, 2026 meeting, and the board approved the 1-for-50 ratio on September 24, 2026. Every 50 issued and outstanding common shares became one new common share; the consolidation did not modify common-share rights or preferences. Proportionate adjustments were made to exercise or conversion prices and the number of common shares underlying outstanding equity awards, convertible securities, warrants, and equity incentive plans. Fractional shares were rounded down, with cash paid in lieu.
Medicus Pharma Ltd. effected a 1-for-50 consolidation of its issued and outstanding common shares, effective October 12, 2026; the shares began trading on a post-consolidation basis on the Nasdaq Capital Market that day. Every 50 common shares were automatically consolidated into one new common share. Shareholders approved a consolidation of up to 1-for-50 on June 3, 2026, and the board approved the 1-for-50 ratio on September 24, 2026.
The consolidation did not modify common-share rights or preferences. Proportionate adjustments were made to exercise or conversion prices and share counts for outstanding equity awards, convertible securities, warrants and equity incentive plans. Fractional shares were rounded down, with cash paid in lieu.
Medicus Pharma Ltd. (MDCX) ownership amendment reports that Dr. Kenneth Melani may be deemed the beneficial owner of 3,248,741 common shares, or 3.6%. Velocity Fund Partners, LP directly owns 2,839,330 shares, or 3.2%, while Melani directly owns 409,411 shares. Melani disclaims beneficial ownership of the fund’s shares except to the extent of his direct ownership. The reported percentages are based on 89,762,721 common shares outstanding as of September 10, 2026.
Medicus Pharma Ltd.'s prospectus identifies 3,245,595 common shares issuable upon exercise of warrants. The company announced a 50-to-one consolidation of its common shares, effective October 12, 2026. Each 50 issued and outstanding common shares will be exchanged for one new common share, and the ticker symbol will remain MDCX.
No fractional shares will be issued; holders otherwise entitled to a fraction will be rounded down and paid cash in lieu. The company also stated that exercise prices and share counts for outstanding equity awards, convertible securities and warrants will be adjusted proportionately. The company said the consolidation is intended to increase the bid price and enable it to regain compliance with Nasdaq's minimum bid price requirement.
Medicus Pharma Ltd. will effect a 50-to-1 consolidation of its common shares effective October 12, 2026. Trading on a consolidated basis is expected to begin at the commencement of trading on October 12, 2026.
Every 50 issued and outstanding common shares will be exchanged for one new common share. No fractional shares will be issued; holdings that would otherwise produce a fraction will be rounded down to the next whole share, with cash paid in lieu. Voting power and share rights will remain unchanged. Proportionate adjustments will be made to exercise prices and shares issuable upon exercise or conversion of outstanding equity awards, convertible securities and warrants, and to shares under equity incentive plans. The company name and MDCX ticker will remain unchanged.
Medicus Pharma Ltd. (MDCX) discloses that its Chief Executive Officer and Executive Chairman, Dr. Raza Bokhari, together with RBx Capital, LP, has beneficial ownership of 4,859,349 common shares of Medicus Pharma, representing 5.3% of the company’s common shares on a beneficial ownership basis.
Dr. Bokhari’s position includes 2,941,176 common shares held directly, 1,125,000 common shares underlying stock options that are currently exercisable or will become exercisable within 60 days, and 793,173 common shares held by RBx Capital, LP, a Delaware limited partnership he controls. RBx Capital’s holdings alone represent 0.9% of the class, based on 89,762,721 common shares outstanding as of September 10, 2026. The securities are held for investment and in connection with Dr. Bokhari’s roles at Medicus Pharma, and the reporting persons may increase or decrease their holdings over time depending on corporate, market, and regulatory considerations.